BRPI0612471A2 - novos compostos como agonistas glp-1 - Google Patents
novos compostos como agonistas glp-1Info
- Publication number
- BRPI0612471A2 BRPI0612471A2 BRPI0612471A BRPI0612471A BRPI0612471A2 BR PI0612471 A2 BRPI0612471 A2 BR PI0612471A2 BR PI0612471 A BRPI0612471 A BR PI0612471A BR PI0612471 A BRPI0612471 A BR PI0612471A BR PI0612471 A2 BRPI0612471 A2 BR PI0612471A2
- Authority
- BR
- Brazil
- Prior art keywords
- glp
- agonists
- new compounds
- compounds
- new
- Prior art date
Links
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN558MU2005 | 2005-05-05 | ||
| IN645MU2005 | 2005-05-31 | ||
| PCT/IN2006/000154 WO2007017892A2 (en) | 2005-05-05 | 2006-05-04 | Novel compounds as glp-i agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0612471A2 true BRPI0612471A2 (pt) | 2016-09-06 |
Family
ID=37727716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0612471A BRPI0612471A2 (pt) | 2005-05-05 | 2006-05-04 | novos compostos como agonistas glp-1 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1891106A2 (pt) |
| JP (1) | JP2008540402A (pt) |
| KR (1) | KR20080021636A (pt) |
| AP (1) | AP2007004227A0 (pt) |
| AU (1) | AU2006277557A1 (pt) |
| BR (1) | BRPI0612471A2 (pt) |
| CA (1) | CA2606894A1 (pt) |
| EA (1) | EA200702419A1 (pt) |
| IL (1) | IL187105A0 (pt) |
| MX (1) | MX2007013655A (pt) |
| NO (1) | NO20075618L (pt) |
| WO (1) | WO2007017892A2 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
| WO2007139589A1 (en) | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
| DK2084182T3 (da) * | 2006-10-03 | 2013-11-04 | Cadila Healthcare Ltd | Antidiabetiske forbindelser |
| WO2009074483A2 (en) * | 2007-12-11 | 2009-06-18 | F. Hoffmann-La Roche Ag | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
| KR101277560B1 (ko) * | 2007-12-11 | 2013-06-25 | 카딜라 핼쓰캐어 리미티드 | 글루카곤 안타고니스트 활성 및 ｇｌｐ-1 아고니스트 활성의 펩티드 유사체 |
| EP2424888A2 (en) * | 2009-05-01 | 2012-03-07 | F. Hoffmann-La Roche AG | Insulinotropic peptide synthesis using solid and solution phase combination techniques |
| CN101891823B (zh) | 2010-06-11 | 2012-10-03 | 北京东方百泰生物科技有限公司 | 一种Exendin-4及其类似物融合蛋白 |
| DK2956160T3 (en) | 2013-02-15 | 2018-08-06 | Mayo Found Medical Education & Res | INSULIN SECRETING POLYPEPTIDE |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| GB0024428D0 (en) * | 2000-10-05 | 2000-11-22 | King S College | Absorption enhancers |
| JP2005501058A (ja) * | 2001-07-31 | 2005-01-13 | ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ | Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用 |
| US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| BR0306706A (pt) * | 2002-01-08 | 2007-03-27 | Lilly Co Eli | peptìdeo glp-1 estendido, métodos de estimulação do receptor de glp-1 em um indivìduo necessitando de normalização de glicose sanguìnea, de tratamento de um indivìduo profilaticamente para diabetes independente de insulina, de redução ou de manutenção do peso corporal, de tratamento da obesidade, e de tratamento de doenças, em um indivìduo necessitando do mesmo, uso de um composto de glp-1, processo de preparação de uma formulação farmacêutica, e, formulação farmacêutica |
| US20060094652A1 (en) * | 2004-02-11 | 2006-05-04 | Levy Odile E | Hybrid polypeptides with selectable properties |
| TW200611704A (en) * | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
| DE102004043153B4 (de) * | 2004-09-03 | 2013-11-21 | Philipps-Universität Marburg | Erfindung betreffend GLP-1 und Exendin |
-
2006
- 2006-05-04 BR BRPI0612471A patent/BRPI0612471A2/pt not_active IP Right Cessation
- 2006-05-04 CA CA002606894A patent/CA2606894A1/en not_active Abandoned
- 2006-05-04 AU AU2006277557A patent/AU2006277557A1/en not_active Abandoned
- 2006-05-04 EA EA200702419A patent/EA200702419A1/ru unknown
- 2006-05-04 KR KR1020077028300A patent/KR20080021636A/ko not_active Withdrawn
- 2006-05-04 EP EP06809915A patent/EP1891106A2/en not_active Withdrawn
- 2006-05-04 AP AP2007004227A patent/AP2007004227A0/xx unknown
- 2006-05-04 JP JP2008509578A patent/JP2008540402A/ja not_active Withdrawn
- 2006-05-04 MX MX2007013655A patent/MX2007013655A/es not_active Application Discontinuation
- 2006-05-04 WO PCT/IN2006/000154 patent/WO2007017892A2/en not_active Ceased
-
2007
- 2007-11-01 IL IL187105A patent/IL187105A0/en unknown
- 2007-11-06 NO NO20075618A patent/NO20075618L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007013655A (es) | 2008-01-24 |
| NO20075618L (no) | 2008-01-30 |
| EA200702419A1 (ru) | 2008-04-28 |
| KR20080021636A (ko) | 2008-03-07 |
| AP2007004227A0 (en) | 2007-12-31 |
| JP2008540402A (ja) | 2008-11-20 |
| IL187105A0 (en) | 2008-02-09 |
| CA2606894A1 (en) | 2007-02-15 |
| WO2007017892A2 (en) | 2007-02-15 |
| AU2006277557A1 (en) | 2007-02-15 |
| EP1891106A2 (en) | 2008-02-27 |
| WO2007017892A3 (en) | 2007-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2020501I1 (lt) | Pakeistieji enaminokarbonilo junginiai | |
| FR18C1017I2 (fr) | Composes de glp-1 acyles | |
| BRPI0718266A2 (pt) | Compostos heterocíclicos como agentes anti-inflamatórios. | |
| BRPI0923786A2 (pt) | compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos | |
| BRPI0810250A2 (pt) | Compostos inéditos | |
| CY2013047I2 (el) | Ενωσεις διαρυλυδαντοϊνης | |
| EP2044055A4 (en) | amide compounds | |
| ATE502948T1 (de) | Substituierte bicyclolactamverbindungen | |
| BRPI0718874A2 (pt) | Compostos orgânicos | |
| NO20084803L (no) | organiske forbindelser | |
| BRPI0718478A2 (pt) | Compostos orgânicos | |
| NO20082030L (no) | Styrt voltametri | |
| CR10049A (es) | Derivados de tiadiazol como agentes antidiabéticos | |
| BRPI0813500A2 (pt) | Compostos antivirais | |
| ATE524477T1 (de) | Aziridinylepothilonverbindungen | |
| CR10353A (es) | Nuevos compuestos. | |
| BRPI0712902A2 (pt) | compostos orgânicos | |
| BRPI0811264A2 (pt) | Compostos | |
| BRPI0718494A2 (pt) | Derivado de fenilsulfamoil benzamida como antagonistas de bradicinina | |
| NO20055686D0 (no) | Sammensetning | |
| BRPI0809996A2 (pt) | Compostos | |
| DE602006018127D1 (de) | Acetylenderivate | |
| DK1937650T3 (da) | Heterocykliske forbindelser | |
| ATE443056T1 (de) | Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen | |
| EP1960358A4 (en) | ANTINEOPLASTIC COMPOUNDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA. |
|
| B11Z | Dismissal: petition dismissal - article 216, par 2 of industrial property law |
Free format text: REFERENTE A PETICAO NO 18070073380/SP DE 05/11/2007. |
|
| B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: O DESPACHO6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0. |
|
| B11M | Decision cancelled [chapter 11.13 patent gazette] |
Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |